|
GRPEL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.66373598126302E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.10702591327572E-15 |
| Normal-vs-Stage2 |
1.808250E-01 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62936331093988E-12 |
| Stage1-vs-Stage2 |
6.185500E-04 |
| Stage1-vs-Stage3 |
5.566200E-02 |
| Stage1-vs-Stage4 |
4.207900E-02 |
| Stage2-vs-Stage3 |
4.10180000000038E-05 |
| Stage2-vs-Stage4 |
2.01589999999641E-05 |
| Stage3-vs-Stage4 |
6.190200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
6.25560003797432E-09 |
| Normal-vs-Asian |
4.58959981131102E-10 |
| Caucasian-vs-AfricanAmerican |
7.643000E-01 |
| Caucasian-vs-Asian |
4.597800E-01 |
| AfricanAmerican-vs-Asian |
4.082600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.96787031114809E-12 |
| Normal-vs-Female |
1.63735691671718E-12 |
| Male-vs-Female |
4.538200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74638081773537E-12 |
| Normal-vs-Age(41-60Yrs) |
7.7715611723761E-15 |
| Normal-vs-Age(61-80Yrs) |
2.81150003278441E-09 |
| Normal-vs-Age(81-100Yrs) |
9.316200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.195800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.583200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.033200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.372600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.229200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.111000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.655800E-03 |
| Classical-VS-Follicular |
1.915560E-03 |
| Classical-VS-Other |
2.887800E-01 |
| Classical-VS-Normal |
1.62558855265615E-12 |
| Tall-VS-Follicular |
1.50487999999172E-05 |
| Tall-VS-Other |
9.650600E-01 |
| Tall-VS-Normal |
1.63236091310637E-12 |
| Follicular-VS-Other |
9.130500E-02 |
| Follicular-VS-Normal |
2.757400E-04 |
| Other-VS-Normal |
1.312500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.61712914965074E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.70550000000436E-06 |
|
|
